Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Teva Takeda to Curb Reminyl Generic Supply following June Listing due to India Lockdown
June 2, 2020
- 6 Japan Drug Makers Net 20% Growth in China Biz Despite COVID-19 Woes
June 1, 2020
- Sumitomo Dainippon to Merge Boston Biomedical, Tolero to Streamline Oncology R&D
June 1, 2020
- Top 4 Wholesalers See Higher Operating Profit Rates in FY2019 Driven by Anticancer Agents, Specialty Products
June 1, 2020
- Chugai Files Patent Litigation against Sawai, Nichi-Iko over Edirol Copies
June 1, 2020
- Takeda Winds Up Development of IBD Drug SHP647
June 1, 2020
- JT, Torii File Topical JAK Inhibitor Corectim for Pediatric Atopic Dermatitis
June 1, 2020
- Otsuka’s Q1 Pharma Sales Surge 13% on Global Brands
May 29, 2020
- Amgen Migraine Med Erenumab Hits Primary Goal in Japan PIII
May 29, 2020
- Bavencio Filed in Japan for Urothelial Carcinoma: Merck Biopharma/Pfizer
May 29, 2020
- Teijin Pharma Files Osteoporosis Drug Abaloparatide in Japan
May 29, 2020
- tella, Cenegenics Begin Clinical Trial of Stem Cell Therapy for COVID-19 in Mexico, Japan Study Planned in Autumn
May 29, 2020
- Sanofi Japan Introduces 2-Week-Rule before Getting Back to Full Operations after COVID-19 Emergency Lift
May 29, 2020
- Drug Makers Exploring “New Normal” in Post-COVID-19; Takeda Plans Major Changes
May 28, 2020
- Towa Voluntarily Recalls Pentasa Generics due to Inadequate Shipment Testing at Contract Manufacturer Nichi-Iko
May 28, 2020
- Japan SGLT2 Inhibitor Market Hits 100 Billion Yen after Weak Start: Jiho Estimate
May 27, 2020
- Fujifilm Eyes FY2020 Trial Launch for Liposome Drug-Keytruda Combo
May 27, 2020
- Shionogi Snaps Up Tetra after PII Alzheimer’s Study Completed
May 27, 2020
- Bayer’s Prostate Cancer Med Nubeqa Now Available in Japan
May 27, 2020
- Japan Pharma Market Tops 10 Trillion Yen for 5th Year Running in FY2019, Keytruda Surges to No.1: IQVIA
May 27, 2020
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…